

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 June 2020 (25.06.2020)



(10) International Publication Number
WO 2020/128446 A3

(51) International Patent Classification:
C07K 16/28 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/GB2019/053569

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:
17 December 2019 (17.12.2019)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1820554.2 17 December 2018 (17.12.2018) GB

(88) Date of publication of the international search report:
30 July 2020 (30.07.2020)

(71) Applicants: **OXFORD UNIVERSITY INNOVATION
LIMITED** [GB/GB]; Buxton Court, 3 West Way, Oxford
OX2 0JB (GB). **MIROBIO LIMITED** [GB/GB]; BioEsca-
lator, Roosevelt Drive, Oxford Oxfordshire OX3 7FZ (GB).

(72) Inventors: **DAVIS, Simon John**; c/o The MRC Weather-
all Institute of Molecular Medicine, John Radcliffe Hos-
pital, Headley Way, Oxford Oxfordshire OX3 9DS (GB).
CORNALL, Richard John; c/o Nuffield Department of
Medicine, University of Oxford, Henry Wellcome Building
for Molecular Physiology, Old Road Campus, Headington,
Oxford Oxfordshire OX3 7BN (GB). **PALUCH, Christo-
pher Douglas**; c/o MiroBio Limited, BioEscalator, Roo-
sevelt Drive, Oxford Oxfordshire OX3 7FZ (GB).

(74) Agent: **HGF LIMITED**; 4th Floor, Merchant Exchange,
17-19 Whitworth Street West, Manchester Greater Man-
chester M1 5WG (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTI-BTLA ANTIBODIES

(57) Abstract: This invention relates generally to antibodies or antigen binding fragments that bind to human B and T lymphocyte attenuator (BTLA) and uses thereof. More specifically, the invention relates to agonistic antibodies that bind human BTLA and modulate its activity, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders.

